Figure 5.

GYY4137 increases MPO activity in arthritic tibiotarsal joints of TRPA1 KO mice. (A) MPO activity in inflamed tibiotarsal joints of GYY4137-treated (50 mg kg⁻¹day⁻¹ i.p.) and vehicle-treated TRPA1 WT and KO animals undergoing K/BxN arthritis on days 2 and 6 shown as emitted photons s⁻¹. (B) Representative bioluminescence images illustrating MPO activity characterized by luminol bioluminescence in tibiotarsal joints of GYY4137- and vehicle-treated TRPA1 WT and KO animals undergoing K/BxN arthritis. Data are shown as mean ± SEM of n = 9–10 mice per group. *p < 0.05 vs. GYY4137-treated TRPA1 WT mice. ^# p < 0.05 vs. TRPA1 KO animals treated with vehicle of GYY4137.